Tapentadol Prolonged Release Reduces the Severe Chronic Ischaemic Pain and Improves the Quality of Life in Patients with Type 2 Diabetes

Abstract

This study has been performed in diabetic type 2 patients with pain due to peripheral artery disease (PAD) in order to evaluate the efficacy and tolerability of tapentadol prolonged release (PR). Methods. 25 patients with type 2 diabetes (13 F and 12 M) were admitted in the study. The evaluation of the analgesic efficacy of tapentadol PR was based on both the assessment of the intensity of the pain (NRS scale from 0 to 10) and the nature of the pain (DN4 questionnaire) and on assessment of the patient's quality of life and state of health (SF-12 Health Survey). Study duration was 3 months: a baseline visit and follow-up included visits after 1 week, 1 month, 2 months, and 3 months. Results. At the beginning of the study, the mean intensity of the pain was 7.88 ± 1.17 on the NRS scale and at visit 2 it reduced in a statistically significant way; at the end of the treatment with tapentadol PR, the mean intensity was 2.84 points on the NRS scale. Conclusion. In type 2 diabetic patients with chronic severe pain due to PAD, tapentadol PR reduced pain intensity, improving the quality of life.

<p>Tapentadol for neuropathic pain: a review of clinical studies</p>

“…In comparison to baseline, at month 3 of treatment pain NRS significantly declined from 7.9±1.2 to 2.8±2.3, DN 4 from 4.0±1.2 to 1.2±1.5 and the number of NP patients from 18 to four patients (72 vs 16%) (Mann–Whitney U test; P <0.01) 61. During treatment with tapentadol, the quality of sleep and the physical and mental components of SF-12 Health Survey improved significantly ( P <0.01), suggesting the potential efficacy of tapentadol PR in this setting 61…”

“…Given its dual mechanism of action, tapentadol may be considered suitable for this condition 19,45,46,77. Tedeschi et al 61 investigated the effects of a 3-month therapy with tapentadol PR (final mean dose 186.4±56.0/day) in 25 diabetic patients with peripheral artery disease at lower extremities; 24 (96%) patients had also skin ulcers and 18 (72%) patients NP with intense paresthesia and allodynia (DN 4 ≥4) 61. In comparison to baseline, at month 3 of treatment pain NRS significantly declined from 7.9±1.2 to 2.8±2.3, DN 4 from 4.0±1.2 to 1.2±1.5 and the number of NP patients from 18 to four patients (72 vs 16%) (Mann–Whitney U test; P <0.01) 61.…”

“…Tedeschi et al 61 investigated the effects of a 3-month therapy with tapentadol PR (final mean dose 186.4±56.0/day) in 25 diabetic patients with peripheral artery disease at lower extremities; 24 (96%) patients had also skin ulcers and 18 (72%) patients NP with intense paresthesia and allodynia (DN 4 ≥4) 61. In comparison to baseline, at month 3 of treatment pain NRS significantly declined from 7.9±1.2 to 2.8±2.3, DN 4 from 4.0±1.2 to 1.2±1.5 and the number of NP patients from 18 to four patients (72 vs 16%) (Mann–Whitney U test; P <0.01) 61. During treatment with tapentadol, the quality of sleep and the physical and mental components of SF-12 Health Survey improved significantly ( P <0.01), suggesting the potential efficacy of tapentadol PR in this setting 61…”

Pain Management in People with Diabetes-Related Chronic Limb-Threatening Ischemia

“…However, it is important to stress that there is little research evaluating the risks and benefits of integrating palliative care into usual diabetic foot care, although it is possible to make some clinically meaningful recommendations. Some analgesic drugs and vasoactive substance such as tapentadol prolonged release and pentoxifylline are used to reduce the severe chronic ischemic pain with LEAD [ 66 , 67 ]. Propionyl-L-carnitine (PLC) can reduce analgesic consumption and pain perception [ 68 ].…”

Insights on the current status and advancement of diabetes mellitus type 2 and to avert complications: An overview

“…27 have assessed the potential and tolerance ability of tapentadol, a drug that serves as both μ‐opioid receptor and nor‐epinephrine reuptake inhibitor in patients with T2DM and the ischemic pain drug was tested for its analgesic potential. The results proved that it was effective in controlling chronic ischemic pain with T2DM 27. Authors added that tapentadol PR has slowed down the intensity of pain and it relieved neuropathic indications, thus elevating the quality of life of patients.…”